New
Director of Marketing, Diagnostics - Lucent Diagnostics
Quanterix | |
tuition assistance, 401(k)
| |
United States, Massachusetts, Billerica | |
Apr 02, 2026 | |
|
Director of Marketing, Diagnostics - Lucent Diagnostics Billerica, MA - Hybrid Quanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With more than 3,400 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company, adding multiplexed tissue imaging with single-cell resolution to its portfolio. Together, the combined company offers a uniquely integrated platform that connects biology across blood and tissue-advancing precision medicine from discovery to diagnostics. ROLE SUMMARY: The Director of Marketing, Diagnostics at Lucent Diagnostics, a Quanterix Brand, will play a critical role in developing and executing the marketing strategy for Lucent Diagnostics diagnostic product(s) in advance of and following 510(k) FDA approval.
This role requires deep expertise in both clinical marketing and payer marketing, with the ability to bridge scientific, clinical, and economic value propositions. The ideal candidate is a strategic marketer who can operate effectively in a pre-commercial, first-mover environment, influence cross-functional stakeholders across Lucent Diagnostics and Quanterix and build foundational marketing and market development programs that will scale post-approval. A key part of this role is driving early testing adoption and market activation to accelerate awareness, engagement, and uptake ahead of launch.
This role will be instrumental in defining product positioning, shaping category and market development strategy, developing market access and reimbursement approaches, and preparing the organization for successful launch and early customer adoption. The Director will partner closely with commercial leadership to help establish brand presence, generate market demand, and position Lucent Diagnostics as a thought leader within an emerging diagnostic category.
WHAT YOU'LL DO: Strategy & Positioning
Clinical Marketing
Payer & Market Access Marketing
Launch Readiness & Commercial Enablement
Brand, Demand Generation & Thought Leadership
BASIC QUALIFICATIONS:
PREFERRED QUALIFICATIONS:
EXPECTATIONS, COMPETENCIES, SKILLS & ABILITIES:
WHY YOU'LL LIKE WORKING WITH US: Why Join Lucent Diagnostics, a Quanterix brand?
This is a unique opportunity to help shape the commercial foundation of a transformative diagnostic technology at a pivotal moment in Lucent's journey, while being backed by Quanterix's established leadership in ultra-sensitive diagnostics. You will play a key role in defining how this product category is introduced, positioned, valued, and adopted across the healthcare system. Our Technology:
From discovery to diagnostics, Quanterix's ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. Simoa technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Our industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology, and infectious disease.
Akoya Biosciences, a Quanterix company, is The Spatial Biology Company-bringing tissue context to life through high-resolution, single-cell imaging. Akoya's spatial phenotyping platforms help researchers visualize and measure how cells organize and interact within tissue to influence disease progression and therapeutic response. From discovery through clinical research, Akoya offers a full continuum of solutions, including PhenoCycler, PhenoImager Fusion and HT, and PhenoCode Panels. As part of Quanterix, Akoya complements a leading portfolio of ultra-sensitive biomarker detection technologies, together enabling a more complete view of biology and disease across both tissue and blood.
Our Commitment to Employees: At Quanterix, our values are based on: Team, Innovation, Customer and Owner.
Team: Challenge assumptions, not the person. Respect diversity of thought and hold ourselves to lofty standards
Innovation: Stay curious, experiment, create and change
Customer: Prioritize and celebrate these pioneers by doing our best to deliver on commitments
Owner: Act with high integrity and in the best interest of Quanterix. Take measured risks and learn from their success and failures
We reward and recognize our employees by offering competitive compensation and a 401k plan with employer match, as well as competitive health, dental, and vision benefits for employees and their dependents. We also offer an unlimited vacation policy to all exempt employees, and a generous PTO policy for non-exempt employees. All employees are eligible for equity, employee stock purchase plan, a performance bonus, and 1:1 financial counseling/planning. We also offer Tuition Assistance. We have a free, state-of-the-art onsite fitness center for all employees. To keep you fueled up, we provide onsite employees with free snacks and drinks every day!
DIVERSE & INCLUSIVE WORKPLACE: Quanterix is committed to a Diverse and Inclusive workplace. We strive to recruit candidates who will bring inclusive mindsets and contribute to our values.
Quanterix is an Equal Opportunity Employer and does not discriminate based on race, national origin, gender, gender identity, sexual orientation, protected veteran status, disability, age, or other legally protected status. Quanterix will make reasonable accommodation for qualified individuals with known disabilities, in accordance with applicable law.
| |
tuition assistance, 401(k)
Apr 02, 2026